Kitov Pharma

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced it will expand the planned Phase 1/2 clinical trial of NT-219 with cetuximab trial in patients with recurrent or metastatic head and neck cancer, to also include evaluation of NT-219 as monotherapy treatment in patients with advanced solid tumors.

Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers

Tufin Software Technologies Ltd

Tufin Software Technologies' (TUFN) CEO Ruvi Kitov on Q4 2019 Results - Earnings Call Transcript

Patent Provides Coverage Until 2035 and Strengthens Company’s IP Portfolio

Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24

TEL AVIV, Israel, Jan.  24, 2020  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt from the European Patent Office (EPO) of a Notice of Intention to Grant for its patent application entitled “Combinations of IRS/STAT3 Dual Modulators and Anti-Cancer Agents for Treating Cancer.”  The patent, which expires in 2036, covers the treatment of NT-219, the company’s novel dual inhibitor of IRS 1/2 and STAT3, in combination with EGFR antibodies and inhibitors.

Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors

TEL AVIV, Israel, Jan.  09, 2020  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has appointed Bertrand Liang, M.D., Ph.D., as its Chief Medical Officer.  Dr. Liang brings to Kitov extensive experience leading clinical development programs in oncology, and he will lead the medical affairs of Kitov in the development of its oncology pipeline including,  CM-24, a novel checkpoint inhibitor, and NT-219, a novel small molecule targeting cancer drug resistance pathways. Kitov intends to initiate clinical trials for both programs in 2020.  

Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer

TEL AVIV, Israel, Jan.  08, 2020  (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced acquisition of privately-held, FameWave Ltd.  The acquisition adds CM-24, a first-in-class inhibitor with a unique and differentiated mechanism of action of a multi-role immune checkpoint inhibition, to Kitov’s oncology pipeline. CM-24 has demonstrated a favorable safety and tolerability profile and an initial signal of monotherapy efficacy in a phase 1 clinical study.  As previously announced, Kitov, in collaboration with Bristol-Myers Squibb Company, intends to initiate a phase 1b/2a clinical trial of CM-24 in combination with Bristol-Myers Squibb’s nivolumab (Opdivo®) in patients with non-small cell lung cancer in the second half of 2020.  

Kitov Pharma Announces Closing of FameWave Acquisition

TEL AVIV, Israel, Jan.  08, 2020  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that, after its delivery of written notice to Nasdaq of its intention to cure the deficiency concerning the minimum $1.00 bid price per share Nasdaq listing requirement during an additional compliance period, on January 7, 2020, it received notification from the Nasdaq Listing Qualifications Department that it has been granted an additional 180-calendar day compliance period, or until July 6, 2020, in order to regain compliance with such listing requirement. 

Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule

Kitov Pharma recently updated their Consensi commercial agreement with Coeptis Pharmaceuticals. I review the original and updated agreement and provide my thoughts on the amendments.

Kitov: Consensi Commercial Update Supports Value Buy

TEL AVIV, Israel, Oct.  11, 2019  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the amendment of the marketing and distribution agreement with Coeptis Pharmaceuticals and provided an update on the upcoming launch of Consensi in the U.S:

Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis  and Provides Update on the Upcoming Launch of Consensi™ in the U.S

TEL AVIV, Israel, Oct.  02, 2019  (GLOBE NEWSWIRE) --    Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the appointment of Eric K. Rowinsky, M.D., as chairman of its board of directors.

Kitov Pharma Appoints Eric K. Rowinsky, M.D.

Kitov Pharma presented encouraging NT-219 data that confirmed its mechanism of action in reversing drug resistance in mouse models. The company is planning on submitting an IND before year-end.

Kitov Pharma: NT-219 Data Reveals Ability To Reverse Pancreatic Cancer Drugs Resistance And The Market Doesn't Care

Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, presented newly released proof-of-concept data showing evidence of NT-219 mechanism of action in reversing cancer drug resistance in PDX models.

Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance

Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q2 2019 Results - Earnings Call Transcript

TEL AVIV, Israel, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that Isaac Israel, CEO, and Gil Efron, Deputy CEO and CFO, will participate in the H.C. Wainwright 21st Annual Healthcare Conference that is being held in New York on September 8-10, 2019.  

Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

TEL AVIV, Israel, Aug.  29, 2019  (GLOBE NEWSWIRE) --   Kitov Pharma Ltd.  (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that Kitov’s subsidiary, TyrNovo, will present new data at the  American Association for Cancer Research (AACR) Pancreatic Cancer: Advances in Science and Clinical Care  conference being held September 6 – 9, 2019 in Boston.

Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference

Kitov Pharma's Consensi is close to launching and will mark the company's transition into a commercial-stage company. However, the stock trades under $1 and is at risk for delisting.

Kitov: Q4 Becoming A Make Or Break For Investors

Kitov is in the final stages of acquiring FameWave and their promising oncology agent CM-24. This acquisition now makes a Kitov an oncology-focused company.

News for Kitov Pharma Stock (KTOV)